JP2025060686A5 - - Google Patents

Info

Publication number
JP2025060686A5
JP2025060686A5 JP2024218275A JP2024218275A JP2025060686A5 JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5 JP 2024218275 A JP2024218275 A JP 2024218275A JP 2024218275 A JP2024218275 A JP 2024218275A JP 2025060686 A5 JP2025060686 A5 JP 2025060686A5
Authority
JP
Japan
Prior art keywords
composition
atrasentan
human subject
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024218275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025060686A (ja
Filing date
Publication date
Priority claimed from JP2022537007A external-priority patent/JP7624995B2/ja
Application filed filed Critical
Publication of JP2025060686A publication Critical patent/JP2025060686A/ja
Publication of JP2025060686A5 publication Critical patent/JP2025060686A5/ja
Pending legal-status Critical Current

Links

JP2024218275A 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法 Pending JP2025060686A (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201962949115P 2019-12-17 2019-12-17
US62/949,115 2019-12-17
US202063005003P 2020-04-03 2020-04-03
US63/005,003 2020-04-03
US202063072699P 2020-08-31 2020-08-31
US63/072,699 2020-08-31
US202063084739P 2020-09-29 2020-09-29
US63/084,739 2020-09-29
US202063125205P 2020-12-14 2020-12-14
US63/125,205 2020-12-14
JP2022537007A JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法
PCT/US2020/065311 WO2021126977A1 (en) 2019-12-17 2020-12-16 Methods of treating iga nephropathy with atrasentan

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022537007A Division JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法

Publications (2)

Publication Number Publication Date
JP2025060686A JP2025060686A (ja) 2025-04-10
JP2025060686A5 true JP2025060686A5 (enExample) 2025-10-27

Family

ID=76478538

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法
JP2024218275A Pending JP2025060686A (ja) 2019-12-17 2024-12-12 アトラセンタンによるｉｇａ腎症を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022537007A Active JP7624995B2 (ja) 2019-12-17 2020-12-16 アトラセンタンによるｉｇａ腎症を治療する方法

Country Status (13)

Country Link
US (11) US20210353593A1 (enExample)
EP (1) EP4076652B1 (enExample)
JP (2) JP7624995B2 (enExample)
KR (1) KR20230015874A (enExample)
CN (3) CN116327758A (enExample)
AU (1) AU2020404984A1 (enExample)
BR (1) BR112022012075A2 (enExample)
CA (1) CA3161516A1 (enExample)
IL (1) IL293921A (enExample)
MX (1) MX2022007471A (enExample)
PH (1) PH12022551456A1 (enExample)
TW (1) TWI875895B (enExample)
WO (1) WO2021126977A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293921A (en) 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
CN114910647A (zh) * 2022-05-07 2022-08-16 浙江大学 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用
WO2023220930A1 (en) * 2022-05-17 2023-11-23 Increvet, Inc. Veterinary pharmaceutical formulations cross-references to related applications
CA3252232A1 (en) * 2022-05-19 2023-11-23 Chinook Therapeutics, Inc. METHODS OF TREATMENT OF SEGMENTAL AND FOCAL GLOMERULOSCLEROSIS WITH ATRASENTAN
WO2024073672A1 (en) 2022-09-30 2024-04-04 Travere Therapeutics, Inc. Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
IL320469A (en) * 2022-10-28 2025-06-01 Chinook Therapeutics Inc Treatment of IGA nephropathy with an endothelin receptor antagonist and an APRIL-binding antibody
AU2023378052A1 (en) 2022-11-07 2025-05-29 Chinook Therapeutics, Inc. Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5236940A (en) 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US20020062121A1 (en) 1995-05-16 2002-05-23 Karl Tryggvason Perfusion apparatus and methods for pharmaceutical delivery
PT885215E (pt) 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
US20040191774A1 (en) 2001-09-11 2004-09-30 Moskowitz David W Endothelin-1 promoter polymorphism
MXPA04009234A (es) 2002-03-22 2005-01-25 Kissei Pharmaceutical Agente preventivo o terapeutico para enfermedades renales.
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US20030229906A1 (en) 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
US9388427B2 (en) 2002-12-02 2016-07-12 Biovec, Llc In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
DE602005022871D1 (de) 2004-06-07 2010-09-23 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
JP2008513481A (ja) 2004-09-17 2008-05-01 アボット・ラボラトリーズ アトラセンタン塩酸塩の結晶形２
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
WO2007109244A2 (en) 2006-03-21 2007-09-27 Morehouse School Of Medicine Novel nanoparticles for delivery of active agents
MX2008012276A (es) * 2006-03-27 2008-10-08 Genentech Inc Metodos para el tratamiento de alteraciones del riñon.
SG174050A1 (en) 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
CA2667364A1 (en) 2007-01-16 2008-07-24 Musc Foundation For Research Development Compositions and methods for diagnosing, treating, and preventing prostate conditions
CN101801936B (zh) 2007-07-31 2012-10-03 吉利德科罗拉多公司 安立生坦的代谢物和衍生物
CA2904447C (en) 2007-08-22 2017-01-03 Abbvie Deutschland Gmbh & Co Kg Therapy for complications of diabetes
US20120083421A1 (en) 2008-10-16 2012-04-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan)
EP2413930A4 (en) 2009-03-31 2012-09-26 Ligand Pharm Inc ORAL FORMULATION OF ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS BASED ON DIPHENYLSULFONAMIDE TO TREAT HIGH BLOOD PRESSURE AND DIABETIC NEPHROPATHY
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
WO2012014663A1 (ja) 2010-07-28 2012-02-02 日本電気硝子株式会社 蛍光体封入用毛細管の製造方法、蛍光体封入用毛細管、波長変換部材及び波長変換部材の製造方法
HK1220209A1 (zh) * 2013-03-08 2017-04-28 Abbvie Inc. 治疗急性肾损伤的方法
AU2014259961A1 (en) 2013-04-30 2015-11-05 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
SG11201600107RA (en) 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
WO2016073846A1 (en) * 2014-11-07 2016-05-12 Abbvie Inc. Methods of treating ckd using predictors of fluid retention
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170014386A1 (en) 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
MA43260A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
UA127339C2 (uk) 2016-01-05 2023-07-26 Юніверсіті Оф Лестер СПОСІБ ПРОФІЛАКТИКИ АБО ЗМЕНШЕННЯ УРАЖЕННЯ НИРОК У СУБ'ЄКТА, ЩО СТРАЖДАЄ НА СТЕРОЇДЗАЛЕЖНУ ІМУНОГЛОБУЛІН-А-НЕФРОПАТІЮ (IgAN)
CN114788823A (zh) * 2016-10-13 2022-07-26 特拉维尔治疗公司 用于治疗肾脏疾病或病症的联苯磺酰胺化合物
CN110177549A (zh) 2016-11-23 2019-08-27 坎莫森特里克斯公司 治疗局灶性节段性肾小球硬化的方法
SG11202002975YA (en) 2017-10-11 2020-04-29 Chemocentryx Inc Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
MA51203A (fr) 2017-11-30 2020-10-07 Idorsia Pharmaceuticals Ltd Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
US20220304979A1 (en) 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
IL293921A (en) * 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
JP2023521169A (ja) 2020-04-10 2023-05-23 チヌーク セラピューティクス，インコーポレイテッド 糖尿病性腎疾患の処置方法
US20220243994A1 (en) 2021-02-04 2022-08-04 Northrop Grumman Systems Corporation Metal woodpile capillary wick

Similar Documents

Publication Publication Date Title
JP2025060686A5 (enExample)
EP4512397A2 (en) New use of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi)
US10206919B2 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
JP2024127897A5 (enExample)
US9320727B2 (en) Combinations of SGLT 2 inhibitors and antihypertensive drugs
TWI406858B (zh) 炎症性腸道疾病治療藥
Dominguez Rieg et al. New functions and roles of the Na+-H+-exchanger NHE3
Fenier et al. Enalapril improved renal function and proteinuria in chronic glomerulopathies
WO2015129750A1 (ja) 慢性腎臓病の進行抑制又は改善剤
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
EP3090744A1 (en) Pharmaceutical complex formulation comprising angiotensin ii receptor blocker and hmg-coa reductase inhibitor
CN105358148A (zh) 用于治疗肾小球疾病的losmapimod
JP7668386B2 (ja) １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
US20110130421A1 (en) Methods and Compositions for the Treatment of Chronic Renal Hypertension
Sahai et al. Pharmacology of the Therapeutic Approaches of Gout
CN100453081C (zh) 用于治疗糖尿病性肾病的吡啶基亚磺酰氨基嘧啶
SG186798A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
RU2741426C1 (ru) Никотинамид для лечения дислипидемии
CN102485227B (zh) 一种药物组合物及其用途
CN101014333A (zh) 包含洛索洛芬的口服组合物
WO2022225044A1 (ja) カリウム吸着薬を有効成分とする慢性腎不全（ｃｋｄ）合併高カリウム血症患者の予後改善剤
Ye et al. Nonsteroidal anti-inflammatory drug use and acute kidney injury in nephrectomies: A retrospective propensity score-matched cohort study
Groothoff et al. Long-Term Nedosiran Safety and Efficacy in Primary Hyperoxaluria Type 1 (PH1): Interim Analysis of PHYOX3: TH-PO1128
US8952011B2 (en) Compositions and methods for the treatment of nasal conditions
JP2025527620A (ja) チロシンキナーゼ阻害剤ボドバチニブを使用した慢性骨髄性白血病を治療する方法